Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib Consolidation Post-Allo-SCT in IDH2-Mutated AML/MDS
NCT04522895Phase 2Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Aug 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enasidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Heinrich Heine University Düsseldorf. Started Aug 2020; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04522895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522895.